Baxter International (BAX) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Baxter International (BAX) right now is Margin and operational turnaround: New CEO Andrew Hider brings a lean-manufacturing and continuous-improvement playbook aimed at reversing the sharp operating-margin compression seen recently. Revenue (TTM, continuing ops) is ~$10.7B. If that keeps playing out, the setup is favourable; the risk to it is the Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. No one can predict where BAX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Baxter International (BAX) higher?
1. Margin and operational turnaround
New CEO Andrew Hider brings a lean-manufacturing and continuous-improvement playbook aimed at reversing the sharp operating-margin compression seen recently. Management describes early progress in stabilizing the business and strengthening execution. Success here is the central lever for the equity.
2. Deleveraging after the Vantive sale
Baxter used proceeds from the roughly $3.8 billion Vantive kidney care divestiture to cut debt, but long-term debt still sits around $8.6 billion against about $2 billion of cash. Management has named debt paydown as the immediate priority for excess cash until leverage reaches roughly 3x, which would free up financial flexibility over time.
3. Infusion systems and connected-care portfolio
The Novum IQ pump platform has driven double-digit US infusion-systems gains when shipping normally, and the Hillrom connected-care hardware adds recurring hospital exposure. Resolving the Novum LVP shipment hold and realizing Hillrom synergies are key to reaccelerating growth.
4. Essential hospital supply demand
Baxter sells mission-critical, high-volume consumables (IV fluids, injectables, sets) that hospitals need regardless of the economic cycle, giving the base business durable, defensive demand. That recurring nature underpins revenue even as the company reshapes its portfolio.
What could weigh on BAX?
The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.6 billion long-term) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. The turnaround is early and could take longer than management projects.
Where BAX trades today
A forecast starts from where the stock actually is. These are BAX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for BAX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a BAX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the BAX guide and whether BAX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the BAX outlook
The bottom line: what is driving Baxter International (BAX) is Margin and operational turnaround, with revenue (ttm, continuing ops) at ~$10.7B. If that keeps playing out the setup is favourable; the risk is the Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. No one can predict the price, so treat any BAX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on BAX
- BAX stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is BAX a buy? (the case for, the risks, and a framework to decide)
- Does BAX pay a dividend?
Build a basket around BAX with Walnut
Use Baxter International as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Baxter International (BAX)?
+
No one can reliably predict where BAX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Baxter International higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive BAX higher?
+
The main growth drivers are Margin and operational turnaround; Deleveraging after the Vantive sale; Infusion systems and connected-care portfolio. Whether they play out is the real question, not a guaranteed path.
What are the risks to BAX?
+
The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.6 billion long-term) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. The turnaround is early and could take longer than management projects.
Will BAX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Baxter International's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is BAX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the BAX "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.